Schrodinger is trading 5% up at $20.48, with no clearly disclosed company-specific catalyst directly explaining the September 1, 2026 move.
- The company announced participation in the Morgan Stanley Global Healthcare Conference, scheduled for September 14, but the release did not link the event to trading activity.
- Broader software weakness and risk-off markets do not explain the stock’s opposite-direction gain.